Compare F5 Inc (FFIV) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Illumina, Inc. — how do they compare? F5 Inc trades at $400.87 (market cap $23.79B), while Illumina, Inc. trades at $187.63 (market cap $28.32B). The key difference: Illumina, Inc. is the larger of the two by market cap. Which is the better fit depends on your goals.
| FFIV | ILMN | |
|---|---|---|
Market Cap | $23.79B | $28.32B |
Sector | Technology | Health |
52-Week High | $431.26 | $194.33 |
52-Week Low | $223.99 | $91.00 |
Enterprise Value | $22.60B | $29.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 Networks (FFIV) trades at $419.00, down 2.84% on the day, but remains in a bullish technical trend above key support levels. The company demonstrates strong fundamental momentum with revenue growth to $3.09B in 2025 and consistent earnings beats, including a recent Q1 2026 EPS of $3.90 against a $3.46 expectation. Recent news highlights strategic expansion into AI security, including the acquisition of SurePath AI (GeekWire, 2026-06-26).
The outlook is supported by robust profitability and strategic positioning in application security, but elevated valuation multiples (P/E 34.61, P/S 7.6) and a high current price relative to the analyst consensus target of $397.00 present near-term valuation risk. The primary investment opportunity lies in the company's execution on its AI security platform growth, while risks include competitive pressures and the stock's premium pricing.
Illumina (ILMN) trades at $191.20, up 0.61% with strong technical momentum near 52-week highs. The company shows robust fundamentals with consistent earnings beats, 19.42% net margin, and improving cash flow. Recent leadership appointments and product launches support growth narrative. Technical indicators show bullish momentum with support at $188 and resistance at $194.
Outlook remains positive with strong sequencing demand and margin expansion driving recovery. Risks include competition from Roche's new sequencer and China market weakness. Analyst consensus is bullish with 51% buy ratings but price target of $174.44 suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
